“In case if FDA come back say required p3 trial

“In case if FDA come back say required p3 trial instead approval, what would be the SP $ will go least/bottom. Just hypothetical question.”

IMO, there are 2 scenarios if the FDA asks for a larger trial for M2M:

1. CYDY signs a licensing agreement with a BP for COVID19 and the M2M trial enrolls quickly with their help, with approval in the next 2-3 months, maybe sooner. I believe the SP may stay stable at that point, or slightly increase with uplisting and the partnership announcement.

2. CYDY doesn’t sign a licensing agreement and has to go the phase 3 M2M trial alone. I believe we might see a significant pullback if this happens, possibly 30-50%. Why? Because it may take months to enroll a larger trial with CYDY going it alone and most people are here to make quick money, not wait until the end of the year.

My hope is that the data from both trials is good and that Fox News and other outlets will jump on the data, just like they did following the first 11 patients. I have a feeling many of those interviewers are waiting for this data and will interview NP and Dr. BP following release. That will put us in mainstream and in front of the President and others and the likelihood of approval will increase.